Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Mar 03, 2021 1:41pm
149 Views
Post# 32706271

RE:I reached out to investor relations

RE:I reached out to investor relations
MAJ427 wrote:
I recently reached out to investor relations and would like to share the response I got.

My main concerns were 1) Is StageZero processing and billing for at least 1,000 Covid tests per day yet? 2) Is Aristotle still launching in Q1 2021? 3) What is the rollout of Aristotle looking like (partners, advertising, etc.)

This is the respone I received back: 
Good morning
 
Thank you for your email.  I am unable to give you daily testing numbers on our COVID tests.  
 
I can confirm that Aristotle is on track to launch this quarter as planned.  The rollout will include partnerships.
 
Given that Aristotle is going to be launched with partnerships in place, pre launch advertising isn't necessary.  I can tell you that a full post launch marketing effort is being put in place.
 
Thank you for your continued support.
 
Cheers Rebecca

I'm quite satisfied with the response I received and am excited for the next few weeks. News of Artistotle is less than one month away! 



 

QUOTE  "Pre launch advertising isn't necessary." UNQUOTE

A lot of wonderful things have been accomplished with this company but advertising is not one of them.  Show me a company with this many positives currently ongoing that leaves investors guessing on their actual status when a simple NR would calm everyone and boost the sp.  We haven't had an update in two months and the sp has fallen from $1.65 to $1.13.  When Aristotle comes out and we get a big percentage gain for the day, the resulting sp will be a lot lower starting at $1.13 versus lets say $1.50. I just don't see the logic........

<< Previous
Bullboard Posts
Next >>